We are joined by touchONCOLOGY European Oncology & Haematology Editor-in-Chief Dr Axel S Merseburger to discuss his highlights from the JAVELIN Bladder 100 Trial (Clinicaltrials.gov identifier: NCT02603432) and the KEYNOTE-426 phase III trial in patients with clear cell renal cell carcinoma (ClinicalTrials.gov identifier: NCT02853331).
1. What are the current unmet needs in the treatment of urothelial carcinoma and how do you see the results of the Javelin Bladder 100 trial impacting the future in this clinical setting? (0:06)
2. What were the main take-home messages from the KEYNOTE-426 phase III trial in patients with clear cell renal cell carcinoma? (3:30)
Speaker disclosure: Axel S Merseburger has no financial or non-financial conflicts of interest in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2020 ASCO Virtual Scientific Program.
Share this Video
Related Videos In Genitourinary Cancers
Axel Merseburger, ASCO GU 2021: Apalutamide in Metastatic Castration-sensitive Prostate Cancer
We were delighted to talk to Editor-in-Chief Prof. Axel Merseburger (Professor and Chairman, Department of Urology, University of Lübeck, Lübeck, Germany) around the TITAN trial in metastatic castration-sensitive prostate cancer (ClinicalTrials.gov Identifer: NCT02489318). The abstract “Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic […]
Alison Birtle, ASCO GU 2021: Peri-operative Chemotherapy versus Surveillance in Upper Tract Urothelial Cancer
touchONCOLOGY joins Dr Alison Birtle (Consultant Oncologist and Honorary Senior Lecturer, Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK) to discuss the updated primary and secondary analysis of the POUT trial in upper tract urothelial cancer (ClinicalTrials.gov Identifier: NCT01993979). The abstract “Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance […]
Ajjai Alva, ESMO 2020 – Pembrolizumab plus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma: the KEYNOTE-361 trial
Dr Ajjai Alva discusses the rationale of pembrolizumab in combination with chemotherapy for the treatment of advanced urothelial cancer and findings from the KEYNOTE-361, and future directions for pembrolizumab research. The late-breaking abstract ‘Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361’ (LBA23) was presented […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!